BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 25585874)

  • 41. Early B-cell factor 3 (EBF3) is a novel tumor suppressor gene with promoter hypermethylation in pediatric acute myeloid leukemia.
    Tao YF; Xu LX; Lu J; Hu SY; Fang F; Cao L; Xiao PF; Du XJ; Sun LC; Li ZH; Wang NN; Su GH; Li YH; Li G; Zhao H; Li YP; Xu YY; Zhou HT; Wu Y; Jin MF; Liu L; Zhu XM; Ni J; Wang J; Xing F; Zhao WL; Pan J
    J Exp Clin Cancer Res; 2015 Jan; 34(1):4. PubMed ID: 25609158
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis.
    Strathdee G; Holyoake TL; Sim A; Parker A; Oscier DG; Melo JV; Meyer S; Eden T; Dickinson AM; Mountford JC; Jorgensen HG; Soutar R; Brown R
    Clin Cancer Res; 2007 Sep; 13(17):5048-55. PubMed ID: 17785556
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group.
    Smol T; Nibourel O; Marceau-Renaut A; Celli-Lebras K; Berthon C; Quesnel B; Boissel N; Terré C; Thomas X; Castaigne S; Dombret H; Preudhomme C; Renneville A
    Leuk Res; 2015 Dec; 39(12):1443-7. PubMed ID: 26467814
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Meis1 programs transcription of FLT3 and cancer stem cell character, using a mechanism that requires interaction with Pbx and a novel function of the Meis1 C-terminus.
    Wang GG; Pasillas MP; Kamps MP
    Blood; 2005 Jul; 106(1):254-64. PubMed ID: 15755900
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia.
    Atanackovic D; Luetkens T; Kloth B; Fuchs G; Cao Y; Hildebrandt Y; Meyer S; Bartels K; Reinhard H; Lajmi N; Hegewisch-Becker S; Schilling G; Platzbecker U; Kobbe G; Schroeder T; Bokemeyer C; Kröger N
    Am J Hematol; 2011 Nov; 86(11):918-22. PubMed ID: 21898529
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Linkage of the potent leukemogenic activity of Meis1 to cell-cycle entry and transcriptional regulation of cyclin D3.
    Argiropoulos B; Yung E; Xiang P; Lo CY; Kuchenbauer F; Palmqvist L; Reindl C; Heuser M; Sekulovic S; Rosten P; Muranyi A; Goh SL; Featherstone M; Humphries RK
    Blood; 2010 May; 115(20):4071-82. PubMed ID: 20237320
    [TBL] [Abstract][Full Text] [Related]  

  • 47. FLT3 and NPM1 mutations in myelodysplastic syndromes: Frequency and potential value for predicting progression to acute myeloid leukemia.
    Bains A; Luthra R; Medeiros LJ; Zuo Z
    Am J Clin Pathol; 2011 Jan; 135(1):62-9. PubMed ID: 21173125
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Study on the correlation between Chinese medical syndrome types and ID4 gene promoter methylation in human acute myeloid leukemia].
    Liu F; Xu RR
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Apr; 32(4):471-3. PubMed ID: 22803425
    [TBL] [Abstract][Full Text] [Related]  

  • 49. DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia.
    Ferreira HJ; Heyn H; Vizoso M; Moutinho C; Vidal E; Gomez A; Martínez-Cardús A; Simó-Riudalbas L; Moran S; Jost E; Esteller M
    Oncogene; 2016 Jun; 35(23):3079-82. PubMed ID: 26434589
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of differentially methylated markers among cytogenetic risk groups of acute myeloid leukemia.
    Qu X; Davison J; Du L; Storer B; Stirewalt DL; Heimfeld S; Estey E; Appelbaum FR; Fang M
    Epigenetics; 2015; 10(6):526-35. PubMed ID: 25996682
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Down-regulation of HOXA4, HOXA7, HOXA10, HOXA11 and MEIS1 during monocyte-macrophage differentiation in THP-1 cells.
    Martino V; Bianchera A; Reia L; Bussolati O; Fazzina R; Marino F; Montemurro L; Tonelli R; Pession A; Gazzola GC; Sala R
    Mol Med Rep; 2009; 2(2):241-4. PubMed ID: 21475819
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CD34 expression on bone marrow blasts is a novel predictor of poor prognosis independent of FlT3-ITD in acute myeloid leukemia with the NPM1-mutation.
    Zhu HH; Liu YR; Jiang H; Lu J; Qin YZ; Jiang Q; Bao L; Ruan GR; Jiang B; Huang X
    Leuk Res; 2013 Jun; 37(6):624-30. PubMed ID: 23473998
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The surface molecular signature of leukemic cells is associated with NPM1 mutations and FLT3 -ITD in patients with de novo acute myeloid leukemia.
    Su L; Gao SJ; Li W; Tan YH; Cui JW; Han W
    Acta Haematol; 2014; 131(3):148-52. PubMed ID: 24192815
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
    Ries C; Loher F; Zang C; Ismair MG; Petrides PE
    Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular genetic tests for FLT3, NPM1, and CEBPA in acute myeloid leukemia.
    Zhang Q; Bai S; Vance GH
    Methods Mol Biol; 2013; 999():105-21. PubMed ID: 23666693
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hypermethylation of CpG sites at the promoter region is associated with deregulation of mitochondrial ATPsyn-β and chemoresistance in acute myeloid leukemia.
    Yang J; Xiao X; Li R; Li Z; Deng M; Zhang G
    Cancer Biomark; 2016; 16(1):81-8. PubMed ID: 26835708
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Aberrant methylation of CCAAT/enhancer binding protein zeta promoter in acute myeloid leukemia.
    Yao DM; Qian J; Lin J; Wang YL; Chen Q; Qian Z; Li Y; Wang CZ; Yang J
    Leuk Res; 2011 Jul; 35(7):957-60. PubMed ID: 21106240
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Array-based DNA methylation profiling in acute myeloid leukaemia.
    Wilop S; Fernandez AF; Jost E; Herman JG; Brümmendorf TH; Esteller M; Galm O
    Br J Haematol; 2011 Oct; 155(1):65-72. PubMed ID: 21790528
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
    Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
    [TBL] [Abstract][Full Text] [Related]  

  • 60. miR-155 regulative network in FLT3 mutated acute myeloid leukemia.
    Salemi D; Cammarata G; Agueli C; Augugliaro L; Corrado C; Bica MG; Raimondo S; Marfia A; Randazzo V; Dragotto P; Di Raimondo F; Alessandro R; Fabbiano F; Santoro A
    Leuk Res; 2015 Aug; 39(8):883-96. PubMed ID: 26055960
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.